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The aim of the present study was to determine whether specific subgroups of schizophrenic patients, grouped according to
electrodermal characteristics, show differences in the N-acetylaspartate/creatine plus choline (NAA / (Cr + Cho)) ratios in the
frontal, cingulate and perirolandic cortices. Skin conductance levels (SCL) and skin conductance responses to auditory
stimulation were measured in 38 patients with schizophrenia and in the same number of matched healthy volunteers (control).
All subjects were submitted to multivoxel proton magnetic resonance spectroscopic imaging. When compared to the control
group, patients presented significantly lower NAA / (Cr + Cho) ratios in the right dorsolateral prefrontal cortex (schizophrenia =
0.95 ± 0.03; control = 1.12 ± 0.04) and in the right (schizophrenia = 0.88 ± 0.02; control = 0.94 ± 0.03) and left (schizophrenia =
0.84 ± 0.03; control = 0.94 ± 0.03) cingulates. These ratios did not differ between electrodermally responsive and non-responsive
patients. When patients were divided into two groups: lower SCL (less than the mean SCL of the control group minus two
standard deviations) and normal SCL (similar to the control group), the subgroup with a lower level of SCL showed a lower NAA
/ (Cr + Cho) ratio in the left cingulate (0.78 ± 0.05) than the controls (0.95 ± 0.02, P < 0.05) and the subgroup with normal SCL
(0.88 ± 0.03, P < 0.05). There was a negative correlation between the NAA / (Cr + Cho) ratio in the left cingulate of patients with
schizophrenia and the duration of the disease and years under medication. These data suggest the existence of a schizophrenic
subgroup characterized by low SCL that could be a consequence of the lower neuronal viability observed in the left cingulate of
these patients.
Key words: Magnetic resonance spectroscopy; Skin conductance; Schizophrenia; N-acetylaspartate; Cingulate region;
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Introduction
The diagnosis of schizophrenia is based on a group of
symptoms, which may differ from patient to patient. Psy-
chotic symptoms such as hallucinations are usually ex-
plained by one mechanism, whereas negative symptoms
by another. Therefore, different neural mechanisms may
be involved to different extents for individual patients with
the same nosological diagnosis (1). An alternative ap-
proach would be to assume the heterogeneity of schizo-
phrenia as a nosological entity and to try to identify homo-
geneous subgroups based on biological and behavioral
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parameters (2).
Electrodermal activity alterations are among the most
cited abnormalities in the psychophysiological study of
schizophrenia and have also been postulated to be predic-
tors of functional outcome (3). The main findings that have
been identified in schizophrenia in this field are low skin
conductance responses to auditory stimulation (SCR) and
abnormalities in the skin conductance level (SCL). These
parameters are often higher during psychotic states of
schizophrenia (4), suggesting that they may be “state” and
not “trait”-related abnormalities. However, they also have a
“trait” property since significant stability of SCR and SCL
over a 1-year period has been reported in both healthy
subjects and schizophrenic patients, especially those who
are clinically stabilized (5).
In one of our studies on electrodermal activity in clini-
cally stabilized schizophrenic patients, we identified a sub-
group with low SCR, low SCL, deficits in selective attention
evaluated by the Stroop task performance and predomi-
nance of negative symptoms (6). In a voxel-based mor-
phometry study, we observed that schizophrenic patients
with low SCL showed lower regional gray matter density in
the right frontal areas compared to healthy volunteers and
to schizophrenic patients with normal SCL (7). Moreover,
prefrontal and anterior cingulate areas were shown to be
more activated during the performance of the modified
Stroop task in schizophrenic patients than in healthy con-
trols (8). These results suggest that frontal and cingulate
areas could be related to the alterations observed in a
subgroup of schizophrenic patients with low SCL and
deficits in selective attention.
Volumetric regional changes observed with cerebral
magnetic resonance imaging (MRI) may be preceded by
changes in regional metabolites (9). Magnetic resonance
spectroscopy (MRS) is a neuroimaging technique that can
quantify chemical cerebral compounds noninvasively (10).
Among the substances identified by MRS, N-acetylaspar-
tate (NAA) is one of the most studied, with altered concen-
trations reported in several neuropsychiatric disorders (11).
NAA is present only in neurons, being a marker of neuronal
integrity (12), although it has been questioned whether
NAA reflects neuronal function alone (13). NAA as a neu-
ronal marker in MRS was reported in many studies, mainly
in patients with epilepsy. Li et al. (14) reported low NAA
levels in the contralateral hippocampus as a prognostic
factor for mesial temporal lobe epilepsy surgery. The same
authors later found normalization of the levels of this com-
pound in patients with temporal lobe epilepsy who were
seizure-free after surgery.
Schizophrenic patients may present alterations in ab-
solute and relative concentrations of NAA in different cere-
bral regions, including the frontal lobe and hippocampus
(15). Relative ratios may be calculated by dividing NAA
concentrations by the concentration of a metabolite whose
concentration would be expected to be stable, such as
creatine (Cr) or choline (Cho). However, a reduction of
NAA in the frontal and cingulate areas of patients with
schizophrenia has not been found consistently (16-18).
These contradictory findings may be due, in part, to the
heterogeneous characteristics of schizophrenia, or to dif-
ferent methodological approaches.
The study of electrodermal activities and NAA / (Cr +
Cho) ratios could be an important step towards the under-
standing of the neurobiology of psychoses in general and
of schizophrenia in particular. Discriminating different sub-
groups can have therapeutic and pathophysiological impli-
cations. We determined the NAA / (Cr + Cho) ratios in
frontal, cingulated and perirolandic areas of subgroups of
schizophrenic patients stratified according to their electro-
dermal activity (SCR or SCL). The perirolandic area was
included in the study as a control area, since it is not
expected to be involved (19). The working hypothesis for
the present study was that patients with low SCR and SCL
would present lower NAA levels in frontal and cingulated
areas.
Patients and Methods
Subjects
Thirty-eight volunteers diagnosed with schizophrenia,
outpatients of the University Hospital of the Ribeirão Preto
Medical School, University of São Paulo, were compared
to 38 healthy controls from the general population re-
cruited by an advertisement in a local newspaper. After
enrollment, healthy volunteers were screened for psychi-
atric and neurologic disorders and were matched to the
patient group. They received remuneration for their partici-
pation in the experiment at a level approved by the local
Ethics Committee.
One of the patients could not be screened, and there-
fore was excluded from the study, along with his respective
control.
The clinical diagnosis of schizophrenia was confirmed
by means of the “Structured Clinical Interview for DSM-IV”,
clinical version (SCID-IV-CV) (20), translated and vali-
dated for the Portuguese language (21). The schizophre-
nia subtypes were: paranoid (68.4%), disorganized (18.4%)
and undifferentiated (13.2%). Patients in acute episodes
of the disorder were excluded after evaluation by the “Brief
Psychiatric Rating Scale” (BPRS) (22), version by Bech et
al. (23), translated and validated for the Portuguese lan-
guage (24). The interviews were performed using the
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Structured Interview Guide for the BPRS (25). Patients
were excluded if their scores were higher than two (pres-
ence of the symptom in a low degree) for each item (except
for the items corresponding to the negative symptoms).
Other exclusion criteria were: a) history of brain injury;
b) other organic mental or neurologic disorders; c) sub-
stance abuse within the last year; d) metallic implants,
foreign bodies, pregnancy, or other conditions that could
prevent patients from being submitted to MRI scanning.
The subjects filled out a standardized questionnaire
about their demographic (sex, age, schooling) and clinical
characteristics (age at the onset and length of the disease,
number of previous hospitalizations, length and type of
medication, dose of antiparkinsonian medications). The
subjects’ handedness was evaluated by the Edinburgh
Handedness Inventory (26) and the socioeconomic level
of the subjects and their respective parents was assessed
by the Brazil Socioeconomic Classification Criteria (Critério
de Classificação Sócio-Econômica Brasil, CCSEB) (27).
Negative symptoms were evaluated by the negative
subscale of the Positive and Negative Syndrome Scale
(PANSS) (28) for schizophrenia, translated and validated
for the Portuguese language (29). Two psychiatrists (A.W.Z.
and J.E.C.H.), experienced in psychopharmacology, blindly
and independently categorized the group of medications
used by each patient according to the potential for anticho-
linergic effects (low, moderate and high), and were in
agreement for 84% of the patients. Disagreements were
solved by consensus between the two evaluators.
Patients and controls were paired according to sex,
age, personal and parents’ socio-economic level, school-
ing, and handedness. Table 1 shows the
clinical and demographic characteristics of
patients and controls.
All subjects and relatives responsible for
them (whenever necessary due to cognitive
constraints) gave written informed consent
after being fully informed of the research pro-
cedure. The project was approved by the
local Ethics Committee (#HCRP 5428/99).
Skin conductance
Electrodermal measurements were per-
formed as described by Lopes-Machado et
al. (6) in a sound-attenuated room under dim
light. Subjects were asked to sit still in a
comfortable armchair and were observed
through a unidirectional mirror. A computer-
controlled, voltage-constant (0.6 V) module
with automatic back off (Contact Precision
Instruments, UK) measured skin conductance.
Two standard silver/silver chloride electrodes (Beckman,
UK) were fixed with adhesive tape in the medial phalanges
of the index and middle fingers of the right hand in right-
handed subjects and of the left hand in left-handed sub-
jects. Contact with the skin was improved with high con-
ductance gel (KY gel, Johnson and Johnson, Brazil).
Measurements were made in two phases: A) Experi-
mental tonic period of pre-stimulation (or rest), which lasted
5 min. In this experiment, the SCL and the number of non-
specific responses (spontaneous fluctuation, with deflec-
tions equal to or greater than 0.05 µS) were recorded. SCL
values were the average of the minute-by-minute log SCL
measured during the resting phase. B) Phasic experiment
of auditory stimulation, which lasted 10 min. The stimulus
consisted of ten 1-s tones of 80 dB, 800 Hz and 10 ms rise
time, which were presented binaurally at pseudo-random
intervals (40-80 s, mean 60 s). In this period, specific
responses were recorded (SCR), and the amplitude of
each response was measured. SCR were considered if
they occurred within a response window of 1 to 5 s after the
tone, and with a variation equal to or greater than 0.05 µs.
The number of non-specific responses, which occurred
during the 20-s interval that preceded each tone, was
recorded.
Subjects were grouped according to their electrodermal
responses to the tones: non-responsive (absence of SCR to
all stimuli) and responsive (at least one SCR response),
according to the strict criterion by Dawson et al. (4)
The subjects were also grouped according to their
basal level of skin conductance. The mean SCL of the
control group less two standard deviations was used as
Table 1. Clinical and demographic characteristics of patients.
Schizophrenic Healthy controls
 patients (N = 37) (N = 37)
Sex (male/female) 26/11 26/11
Age (years) 29.73 ± 1.66 29.43 ± 1.60
Handedness (right/left) 35/2 35/2
Schooling (years) 8.95 ± 0.57 9.57 ± 0.49
Socioeconomic level of subjects 2.78 ± 0.88 2.31 ± 0.61
Socioeconomic level of parents 2.57 ± 0.78 2.60 ± 0.78
Antipsychotic (CPZ, mg) 425.81 ± 37.02
Anticholinergic (atropinea, mg) 485.81 ± 74.37
Years of illness 10.03 ± 1.34
Years on drug 9.72 ± 1.36
No. of hospitalizations 3.16 ± 0.44
Age at onset (years) 19.57 ± 1.06
PANSS-N 22.03 ± 1.33
Data are reported as means ± SEM, unless otherwise stated. CPZ = chlorprom-
azine equivalents (30); PANSS-N = negative subscale of the Positive and
Negative Syndrome Scale. aAtropine equivalents.
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the cut-off to identify schizophrenic patients with low SCL.
Proton magnetic resonance spectroscopy
All subjects were scanned with a 1.5 Tesla magnet with
gradients of 25 mT, model Magnetom Vision (Siemens,
Germany), using a standard transmitter/receiver head coil
of circular polarization. The structural imaging protocol
included a gradient-echo 3-D sagittal acquisition, MPRAGE,
T1-weighted sequence (TE = 4 ms, TR = 9.7 ms, 1-mm
thick slices), and axial, TSE T2-weighted sequence (TE =
90 ms, TR: 4000 ms, 5-mm thick slices). The images were
analyzed to exclude structural abnormalities and to local-
ize the volume-of-interest for spectroscopic analysis. Lo-
calization was consistent among subjects. A print template
image of the ideal positioning was kept in the acquisition
console for constant comparison. Landmarks such as the
central sulcus, the hand motor area, and the superior
frontal sulcus were used as references.
A neurologist (D.A.) with expertise in this technique,
who was blind to the diagnoses or groups, performed all
examinations. Patients and controls were positioned in the
scanner by the same person, using a laser beam to control
the degree of neck hyperextension and rotation.
Proton MRS (1H-MRS) was performed with a multivoxel
sequence (CSI hybrid), PRESS (point-resolved spectros-
copy - TE = 135 ms, TR = 1500 ms) and water suppression
with a selective saturation pulse. The volume-of-interest
was represented by a grid of 64 juxtaposed voxels of 20 x 10
x 10 mm (covering 20 x 80 x 80 mm), positioned above the
corpus callosum, perpendicular to the anterior commissure-
posterior commissure line, over the frontal lobe (Figure 1).
Four voxels over the anterior middle frontal gyrus were
selected to represent the frontal area, four for the perirolandic,
over the primary motor and sensitive areas, and six for the
cingulate region, on both sides of the interhemispheric fis-
sure (Figure 1). Total scanning time for the spectroscopy
sequence was maintained at <10 min, including positioning,
to avoid movement artifacts. Saturation bands were used in
the external voxels to prevent “voxel bleeding” from periph-
eral regions with cranial fat or bone.
Spectroscopic data were processed using the Siemens®
software, with a standard algorithm that included a fast
Fourier transform, zero filling, and apodization, installed in
an auxiliary console workstation (Unix Sun Spark Sys-
tems™). Apodization was performed with a Gaussian filter
centered at 0.0 and with a width of 256 ms. The post-
processing protocol included a polynomial base-line cor-
rection procedure of order 5. The phase was corrected on
the basis of the best fit to the NAA peak, trying to match
both peak borders. Calculating the area under the peak
and fitting were performed automatically by the manufac-
turer’s software. The area was calculated as the integral
under the curve. Fitting was carried out by automatic
triangulation with 10 iterations. Parameters of precession
frequency were set at 2.2 ppm for NAA, 3.0 ppm for Cr, and
3.5 ppm for Cho.
To determine the voxels for analysis (spectrum quality),
the following parameters were used: baseline variation,
definition of the peaks and maximum width at half length of
each peak (less than 10 Hz). Spectra that did not meet these
criteria were excluded from the sample. Manual baseline
and phase correction were performed whenever possible.
Quantitative spectroscopy maps were transferred as
.txt files to Excel (Microsoft®) template tables. The tables
were organized to automatically report NAA, Cr, and Cho
raw numbers, ratios, and asymmetry indexes. Raw num-
Figure 1. Midsaggital (A), axial (B) and coronal (C)
magnetic resonance spectroscopy images of a
normal comparison subject with the representa-
tive voxel box superimposed.
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bers were assumed to be proportional to concentrations.
The NAA / (Cr + Cho) ratios, for each region and each
side, was used for comparison among groups. Therefore,
six measurements were recorded for each patient: frontal
left and right ratios, perirolandic left and right ratios,
cingulated left and right ratios.
Procedure
Subjects were evaluated individually in three sessions,
with a maximum of 30 days between the first and the last.
During the first session, the subjects signed an informed
consent form and were then evaluated in terms of the
inclusion and exclusion criteria, clinical history, and SCID-
IV-CV. In the second session, the patients were once more
evaluated with the BPRS and PANSS – negative subscale.
For every 5 patients evaluated, 1 patient was re-inter-
viewed by a different psychiatrist, who also applied the
tests independently in order to evaluate their reliability
throughout the study. In this session, the subjects were
submitted to skin conductance measurements. In the final
session, the subjects were submitted to 1H-MRS without
sedation. The MRS data were always acquired in non-
clinical settings, away from current clinical MRI studies.
Usually on the weekends, patients and controls were alter-
nated, without the previous knowledge of the radiologist or
the MRI technician.
Analysis of the results
The results of the NAA / (Cr + Cho) ratios for each
region of interest in the schizophrenic and control sub-
groups, organized according to electrodermal responsive-
ness, were submitted to a two-way ANOVA for the factors
diagnosis, responsiveness and interaction, then the Duncan
test was used for post hoc comparison test. The same
results, organized according to the level of basal conduc-
tance, were submitted to a one-way ANOVA.
Correlations between the variables were determined
with the Spearman coefficient of correlation procedure.
The statistical analysis was performed with the Statistical
Package for Social Sciences (SPSS), version 10.0, and
the significance level was set at P ≤ 0.05.
Results
Skin conductance respose
Subjects were divided into four experimental subgroups
according to SCR: responsive schizophrenic (SCHIZ-R; N
= 16), non-responsive schizophrenic (SCHIZ-N; N = 21),
responsive controls (CONT-R; N = 27), and non-respon-
sive controls (CONT-N; N = 10). The demographic, clinical,
and electrodermal conductance characteristics of the four
groups are shown in Table 2.
There was a predominance of men in the responsive
Table 2. Demographic, clinical, and electrodermal conductance characteristics of schizophrenic patients grouped according to
electrodermal responsiveness to auditory stimuli.
Responsive Non-responsive Responsive Non-responsive
schizophrenic patients schizophrenic patients controls controls
(N = 16)  (N = 21) (N = 27) (N = 10)
Sex (male/female) 15/1 11/10+ 21/6 5/5*
Age (years) 30.13 ± 2.03 29.43 ± 2.52 28.07 ± 1.65 33.10 ± 3.82
Handedness (right/left) 15/1 20/1 26/1 9/1
Schooling (years) 10.19 ± 0.82 8.00 ± 0.74 9.74 ± 0.64 9.1 ± 0.60
SF 44.56 ± 8.31 3.95 ± 2.66* 30.00 ± 4.58 3.90 ± 1.89*
SCL 15.59 ± 2.84* 9.94 ± 2.12*+ 23.99 ± 0.51 21.62 ± 0.30
Antipsychotic (CPZ, mg) 458.44 ± 65.58 400.95 ± 42.62
Antipsychotic typicals/atypicals 8/8 9/12
Anticholinergica (low/moderate/high) 7/3/6 5/5/11
Years of illness 11.00 ± 2.02 9.30 ± 1.80
Years on drug 10.53 ± 2.08 9.10 ± 1.83
Hospitalizations 2.94 ± 0.71 3.33 ± 0.56
Age at onset (years) 19.00 ± 1.11 20.00 ± 1.68
PANSS-N 18.44 ± 1.92 24.76 ± 1.62+
Data are reported as means ± SEM, unless otherwise stated. SF = skin conductance spontaneous fluctuation; SCL = skin
conductance levels; CPZ = chlorpromazine equivalents (30); PANSS-N = negative subscale of the Positive and Negative Syndrome
Scale. aPatients categorized, blindly and independently, by two psychiatrists according to the anticholinergic effects of medications
used. *Significantly different than responsive control. +Significantly different than responsive schizophrenics (chi-square, Duncan and
Student t-tests).
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group compared with the non-responsive group. Con-
versely, no significant differences were observed among
the four groups regarding age, schooling and handedness.
There were no differences between the two patient groups
in terms of antipsychotic equivalence (in mg of chlorprom-
azine), anticholinergic potential of the medication used,
number of hospital admissions, age at disease onset,
length of disease, or antipsychotic use. The SCHIZ-N
subgroup showed higher values in the PANSS negative
subscale than the SCHIZ-R subgroup. The subgroups
SCHIZ-N and CONT-N presented significantly less spon-
taneous fluctuations of skin conductance compared with
the SCHIZ-R group. Moreover, the subgroups SCHIZ-N
and SCHIZ-R presented significantly lower levels of basal
skin conductance than the subgroups CONT-N and CONT-
R, and the value of SCHIZ-N was even lower than SCHIZ-R.
The two-way ANOVA indicated a significant effect for
diagnostic factor in the right frontal cortex (F = 9.9; P <
0.01) and cingulate bilaterally (right F = 5.9; P < 0.05/left F
= 7.4; P < 0.01). There was no main effect for the SCR
factor or diagnostic by SCR interaction. The average NAA
/ (Cr + Cho) ratio in the right frontal cortex was significantly
lower for schizophrenic patients (0.95 ± 0.03) than for
controls (1.12 ± 0.04). This was also the finding in the right
cingulate (SCHIZ = 0.88 ± 0.02; CONT = 0.94 ± 0.03), and
left cingulate (SCHIZ = 0.84 ± 0.03; CONT = 0.94 ± 0.03)
comparisons. No differences were observed in SCR in any
of the areas investigated by spectroscopy, nor was there
any interaction between the factors diagnosis and SCR.
Basal conductance level
Figure 2 shows the distribution of subjects according to
their basal conductance level. Three groups are presented.
The schizophrenic patients were divided into two groups,
one with low conductance level (SCHIZ-L; N = 19) and the
other with conductance level similar to that of the controls
(SCHIZ-N; N = 18).
Table 3 shows the clinical and demographic character-
istics of the three subgroups, grouped according to basal
electrodermal conductance levels. No statistically signifi-
cant differences were observed among the three sub-
Figure 2. Scatter diagram of skin conductance levels during a 5-
min rest period. Points indicate mean value for each subject.
Table 3. Demographic, clinical, and electrodermal conductance characteristics of subjects grouped according to basal skin conduc-
tance level.
Schizophrenic patients with low Schizophrenic patients with normal Controls (N = 37)
conductance level (N = 19) conductance level (N = 18)
Sex (male/female) 15/4 11/7 26/11
Age (years) 29.95 ± 2.28 29.50 ± 2.48 29.43 ± 1.60
Handedness (right/left) 17/2 18/0 35/2
Schooling (years) 8.95 ± 0.94 8.94 ± 0.66 9.57 ± 0.49
SCL 2.48 ± 0.42* 22.84 ± 0.87 23.35 ± 0.42
SF 20.16 ± 5.70 22.94 ± 8.73 22.95 ± 3.87
SCR 1.95 ± 0.69 3.17 ± 0.93 3.70 ± 0.56
Electrodermal responsive/non-responsive 7/12* 9/9* 27/10
Antipsychotic (CPZ, mg) 411.32 ± 60.08 441.11 ± 43.63 -
Antipsychotic typicals/atypicals 9/10 8/10
Anticholinergica (low/moderate/high) 5/4/10 7/4/7 -
Years of illness 11.43 ± 1.92 8.56 ± 1.84 -
Years on drug 11.42 ± 1.92 7.92 ± 1.88 -
Hospitalizations 3.63 ± 0.63 2.67 ± 0.60 -
Age at onset (years) 18.53 ± 1.01 20.67 ± 1.89 -
PANSS-N 21.89 ± 1.95 22.17 ± 1.85 -
SCL = skin conductance levels; SF = skin conductance spontaneous fluctuation; SCR = skin conductance orienting response; CPZ =
chlorpromazine equivalents (30); PANSS-N = negative subscale of the Positive and Negative Syndrome Scale. aPatients catego-
rized, blindly and independently, by two psychiatrists according to the anticholinergic effects of medications used. *P < 0.05 compared
to control (Duncan and chi-square tests).
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groups, except for the basal conductance level of sub-
group SCHIZ-L, which was significantly lower than that of
the two other subgroups.
Figure 3 shows the values for NAA / (Cr + Cho) of the
three subgroups with respect to basal electrodermal con-
ductance levels in the frontal, cingulate and perirolandic
areas. Ratios were different comparing patients and con-
trols in the right frontal region. The subgroup of schizo-
phrenics with low basal SCL differed from the control group
in the cingulate, bilaterally. In the left cingulate, this sub-
group (low basal SCL) of schizophrenics also differed from
the other subgroup (normal level) of patients.
Correlations
Negative correlations were observed between age and
NAA / (Cr + Cho) ratios in the right and left cingulate gyrus
for controls (r = -0.39, P < 0.02; r = -0.44, P < 0.01;
respectively) and patients (r = -0.37, P = 0.02; r = -0.43, P
< 0.01, respectively). Among the patients, the NAA / (Cr +
Cho) ratios correlated negatively with duration of disease
(r = - 0.39, P < 0.02) and years on medication (r = -0.41, P
< 0.02) in the left but not in the right cingulate gyrus.
Discussion
In this study, the group of schizophrenic patients had
significantly lower NAA / (Cr + Cho) ratios compared to
controls in the right frontal and bilateral cingulate areas.
There were no differences in the perirolandic areas.
Other results reported in the literature should be treated
with some caution because of methodological differences
among the studies. One of the main limitations of MRS is its
relatively low spatial resolution. In single voxel techniques,
some studies report voxels as large as 8.0 cm3. For that
reason, conclusions at the cellular level cannot be made.
The voxel size in our study was 2.0 cm3, and with volumes
much larger, one must be careful to describe regional
metabolic alterations. A critical review of the methodology
used in 1H-MRS studies of the frontal lobe in schizo-
phrenics (18) selected 6 studies with a methodological
rigor similar to that of the present study, including the
appropriate number of subjects, long echo time (ideal for
NAA quantification) and small voxel volume. From the 6
studies selected, 4 reported similar findings to the present
study, showing NAA reduction in frontal regions (17,31-33)
and 2 reported negative results (16,34).
Greater grey matter volume in the dorsomedial pre-
frontal cortex was associated with better performance in
the Stroop task with respect to interference (35). In this
way, the lower levels of NAA in the right anterior middle
frontal gyrus observed in the present study may reflect
reduction of neuronal viability in this area and might be
associated with the attention deficits previously observed
in schizophrenic patients with low SCL, through the higher
interference time in the Stroop task (6).
The anterior cingulate gyrus is active in cognitive,
motor and affective functions, but it also has an important
role in selective attention and achievement-oriented be-
haviors (36).
Primary motor and sensitive areas did not show any
differences. This result can give some credibility to the
present study, since positive findings in these areas were
not expected a priori.
The NAA / (Cr + Cho) ratios did not differ between
SCHIZ-R and SCHIZ-N. Electrodermal responsiveness to
auditory stimuli failed to identify a subgroup of schizo-
phrenics with lower values of NAA, at least for those areas.
The individual results of basal SCL suggest that two
subgroups of schizophrenic patients can be identified: one
with SCL similar to that of the healthy control, and another
with low SCL. This is a very unusual finding, since a
continuous distribution should be expected here. Previous
studies have shown lower mean SCL in patients compared
to controls (37), but the present study suggests that this
occurs only in one subgroup of patients. There were no
differences between these two subgroups regarding the
mean doses of antipsychotic and anticholinergic medica-
tions or the proportion of patients receiving typical and
atypical antipsychotic agents, which suggests that the
patients’ treatment does not explain the low conductance
levels found for one of the patient subgroups.
Figure 3. NAA / (Cr + Cho) ratio for the control group (N = 37;
open bars), patients with normal conductance levels (N = 18;
stripped lined bars) and schizophrenic patients with low conduc-
tance levels (N = 19; closed bars) in the frontal, cingulate and
perirolandic cortices. Asterisks indicate a statistically significant
difference compared to controls and the plus indicates a signifi-
cant difference between the subgroups of schizophrenics
(ANOVA).
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The results of the present study do not confirm the
observation by Dawson et al. (4), in which a group of
patients showed higher SCL than controls. This discrep-
ancy may have occurred because only patients who were
not in acute episodes were enrolled in our study. It is well-
known that SCL may be higher during acute episodes of
schizophrenia. Age and duration of illness may also ac-
count for the discrepancies between the studies (4). For
instance, the electrodermal nonresponsiveness, negative
symptoms, poor functional outcome, and cognitive deficits
are all more often seen in older patients with longer dura-
tion of illness (3).
The subgroup of patients with low SCL also has lower
NAA / (Cr + Cho) ratio in the left cingulate compared to
controls and to the other subgroup of patients. Thus, it was
possible to identify a subgroup of patients who, in addition
to lower SCL, also have shown lower neuronal viability in
the anterior left cingulate.
Lower neuronal viability may be related to the duration
of the disease. Duration of illness and years on medication
were about 3 years longer in the low conductance sub-
group, although not statistically significant. Moreover, only
in the left cingulate, a negative correlation of the NAA / (Cr
+ Cho) ratios was observed with duration of disease and
years on medication. A correlation between NAA levels in
the anterior cingulate and duration of schizophrenia was
also reported by Ende et al. (38), who showed that this
correlation remained significant even when the levels had
been corrected for the age effect in the control group.
These results differ from those reported by Deicken et al.
(32). A possible explanation for the absence of correla-
tions in their studies could be the longer time of illness in
their sample (mean = 16.5 years). There is evidence
suggesting that a degenerative process of the disorder
may occur more expressively in the first years (36).
A possible influence of the type of antipsychotic drug
used could account for the lower NAA levels observed in
the low SCL subgroup, since typical antipsychotics, differ-
ently from atypical ones, are associated with lower NAA
levels in the anterior cingulate (38). However, the propor-
tion of patients receiving typical and atypical antipsychotics
was the same in the present study. This suggests that the
type of antipsychotic is not likely to explain the differences
in NAA / (Cr + Cho) ratios between the two subgroups.
The lower neuronal viability in the left anterior cingulate
could be related to deficient autonomic responses. Pa-
tients with pure autonomic failure who do not activate
autonomic responses, including skin conductance, in re-
sponse to physical or cognitive efforts, have shown a
smaller volume of gray matter in the left anterior cingulate
(39). Also, Critchley et al. (40), using positron emission
tomography in healthy volunteers, observed that the left
anterior cingulate was activated during the voluntary effort
for relaxation through biofeedback, resulting in reduction
of the level of skin conductance. Such observations sug-
gest that the left anterior cingulate is involved in the inten-
tional modulation of alert states and their peripheral body
repercussions, such as skin conductance. This could be a
physiological explanation to the lower SCL found in our
sample.
The results of the present study suggest a decrease of
neuronal viability in the left anterior cingulate of patients
with schizophrenia, associated with the duration of the
disease and that this change could justify the observed
decrease in SCL. Further studies may possibly identify
cognitive and emotional characteristics specific to this
subgroup of schizophrenic patients.
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